Goldman Sachs has downgraded Novartis AG (NYSE:NVS), citing “limited value driving innovation catalysts in the near term.”
The analyst writes that continued earnings momentum has led to increases in revenue and profit forecasts for fiscal years 2024 and 2025 since the beginning of the year, thanks to upgraded fiscal year 2024 guidance provided in the first and second quarters of 2024.
Also Read: Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs.
Moreover, from a valuation standpoint, Novartis is trading at 14.2 times its projected 2025 EPS, representing an approximately 8% premium over the European Biopharma sector, excluding Novo Nordisk A/S (NYSE:NVO).
Goldman writes the premium has been higher than the average since 2023, which was about 7%, and ...
